Oral care company Colgate-Palmolive stated on Thursday that toothpastes containing zinc or stannous and mouthwash formulas with cetylpyridinium chloride (CPC) neutralize the virus that causes COVID-19 by 99.9% based on laboratory programme Rutgers NJMS.
The studies are part of a Colgate research programme that includes clinical studies among infected people to assess the efficacy of oral care products in reducing the amount of the virus in the mouth, potentially slowing the transmission of the COVID-19 virus. The study was led by Dr David Alland, Chief of Infectious Diseases and director of the Center for COVID-19 Response and Pandemic Preparedness.
In the laboratory studies, which were conducted in partnership with Rutgers New Jersey Medical School's (NJMS) Public Health Research Institute and Regional Biosafety Laboratories, Colgate Total and Meridol toothpastes neutralized 99.9% of the virus after two minutes of contact. Colgate Plax and Colgate Total mouthwashes were similarly effective after 30 seconds. The results suggest that some toothpastes and mouthwashes may help reduce the spread of SARS-CoV-2 by temporarily reducing the amount of virus in the mouth.
In conjunction, the researchers plan to share their findings in December. Additional Colgate-supported clinical research studies on toothpaste and mouthwashes are in early stages at Rutgers, the Albert Einstein Institute in Sao Paulo, Brazil and at the University of North Carolina at Chapel Hill Adams School of Dentistry, with some 260 people with COVID-19 participating in these studies.
Eisai and Nuvation Bio report taletrectinib MAA validated by European regulator
Novo Nordisk's Awiqli once-weekly basal insulin treatment approved by US FDA
Kodiak Sciences reports positive Phase 3 results for Zenkuda in diabetic retinopathy
Clarity Pharmaceuticals signs copper-64 manufacturing agreement with Theragenics
Merck to acquire Terns Pharmaceuticals for USD6.7bn
Maze Therapeutics reports positive Phase 2 data for MZE829 in patients with AMKD
Bio-Techne expands COMET spatial biology platform with new SPYRE Panels and Amplification Kits
CRISM Therapeutics advances Phase 2 glioblastoma trial with initial ChemoSeed batch manufactured
Myosin Therapeutics granted USD2m funding from Florida Department of Health
Clover Biopharmaceuticals reports positive US Phase I data for RSV re-vaccination in older adults
Hope Medicine reports first patient dosed in Phase III trial of HMI-115
Akeso's Phase II trials of AK146D1 and AK138D1 approved in China
Insilico Medicine and ASKA Pharmaceutical expand partnership on women's health targets